Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD38-SADA:177Lu-DOTA in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT05994157Phase 1Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD38-SADA:177Lu-DOTA in non-Hodgkin lymphoma (NHL), sponsored by Y-mAbs Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities (Part A) at 4 weeks, Tumor imaging at 4 weeks and 1 more. Started Apr 2025; status: terminated.
02
Drugs
CD38-SADA:177Lu-DOTA
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05994157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05994157.